Global In Vivo Bioreactor by End User (Research &Development Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Others), By Material Type (Single-use, Glass, Stainless Steel), By Usage (Pilot-scale, Lab-scale, Full-scale), By Capacity (< 1L – Benchtop Unit, 5L-20L, 20L-200L, 200L-1500L, Above 1500L – Large-scale unit) and by Geography – Opportunities & Forecast, 2018-2024
In Vivo Bioreactor is a new approach to regenerate autologous fabricated tissue flaps or bone tissue and transplant it into ectopic site in patient’s body. In Vivo Bioreactor is a revolution for aesthetic reconstruction. Bioreactors are basically similar to external chambers in which biotic tissues can be grown. In Vivo bioreactors can generate fabricated tissues inside human body in natural way without contribution of exogenous elements.
The major driving factor of In Vivo Bioreactor market is adoption of Single-use-bioreactors. Technology upgradation is also helped to grow the In Vivo Bioreactor market. Single-use-bioreactors use disposable bag instead of cultural vessel that increase the efficiency of bioreactors in terms of quality control and procurement. In Vivo Bioreactors minimize the donor side morbidity that decrease the exogenous complexity. Another driving factors of this market are: increasing organ transplantations, growing cell-based research market and biologic manufacturing market. Bioreactors are majorly used to produce monoclonal medicines for cancer, asthma, Crohn’s disease, Psoriasis etc. High cost of organ transplantation as well as limited storage of bioreactors are major restraints in this market. Bioreactors are made by plastic material which is not secure for regular use.
The major key players of this market are: Terumo Corporation, Solaris Biotech, Nipro Corporation, ZETA Holdings GmbH, Bioengineering AG, Medtronic, Merck Millipore Corporation, GE Healthcare, Sartorius AG, Harvard Bioscience, Inc.
The Global In Vivo Bioreactor Market has been segmented on the basis of end user, material types, usage, capacity and key geographies. The research report “Global In Vivo Bioreactor Market” provides in-depth analysis of global In Vivo Bioreactor market based on end user, material types, usage, capacity and major geographies for the forecast period from 2018 to 2024. The report also highlights the major market drivers propelling the growth as well as challenges faced by market participants. The research report provides market size and forecast for the global In Vivo Bioreactor market. In addition, the report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.
Key questions answered in this research report:
1- At what pace is In Vivo Bioreactor market growing? What will be growth trend in future?
2- What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the future?
3- What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in the In Vivo Bioreactor?
4- What are the various application areas and how they are poised to grow?
Market Segments:
• By End User
◦ Research &Development Departments
◦ Biopharmaceutical Manufacturers
◦ Contract Research Organizations
◦ Others
• By Material Type
◦ Single-Use
◦ Glass
◦ Stainless Steel
• By Usage
◦ Pilot-scale production
◦ Lab-scale production
◦ Full-scale production
• By Capacity
◦ < 1L – Benchtop Unit
◦ 5L-20L
◦ 20L-200L
◦ 200L-1500L
◦ Above 1500L – Large-scale unit
• By Geography
◦ Europe
▪ Germany
▪ Spain
▪ UK
▪ France
▪ Italy
◦ North America
▪ USA
▪ Canada
◦ South America
▪ Brazil
▪ Mexico
▪ Argentina
◦ Asia-Pacific
▪ China
▪ Japan
▪ India
▪ South Korea
◦ Middle East and Africa
Leading Market Players:
• Pall Corporation (Danaher Corporation)
• Eppendorf AG
• Merck Millipore Corporation
• Sartorius AG
• GE Healthcare
• Thermo Fisher Scientific Inc.
• ZETA Holdings GmbH
• Bioengineering AG
• Applikon Biotechnology Inc.
• Solaris Biotech
• ALA Scientific Instruments, Inc.
• Getinge AB
• Harvard Bioscience, Inc.
• Lifeline Scientific, Inc. (Organ Recovery Systems, Inc.)
• Livanova PLC
• Medtronic PLC
• Nipro Corporation
• Repligen Corporation
• Spectrum Laboratories, Inc.
• Terumo Corporation
*Other prominent players in the market which can be profiled as a part of customization:
• Praj HiPurity Systems Limited
• Pierre Guerin Technologies
• Infors HT
- Published Date: Feb-2020
- Report Format: Excel/PPT
- Report Code: ICT34A-00-0719
Licensing Options
Single-User License:
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
Global In Vivo Bioreactor by End User (Research &Development Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Others), By Material Type (Single-use, Glass, Stainless Steel), By Usage (Pilot-scale, Lab-scale, Full-scale), By Capacity (< 1L – Benchtop Unit, 5L-20L, 20L-200L, 200L-1500L, Above 1500L – Large-scale unit) and by Geography – Opportunities & Forecast, 2018-2024
$ 4,499.00 – $ 6,649.00